Long-term correction of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integration

Xi Chen; Xuran Niu; Yang Liu; Rui Zheng; Lei Yang; Jian Lu; Shuming Yin; Yu Wei; Jiahao Pan; Ahmed Sayed; Xueyun Ma; Meizhen Liu; Fengxiang Jing; Mingyao Liu; Jiazhi Hu; Liren Wang; Dali Li

doi:10.1016/j.jgg.2022.06.001

Volume 49 Issue 12

Dec. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Genetics and Genomics > 2022 > 49(12): 1114-1126

PDF( 2978 KB)

Long-term correction of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integration

doi: 10.1016/j.jgg.2022.06.001

a. Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China;
b. The MOE Key Laboratory of Cell Proliferation and Differentiation, Genome Editing Research Center, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China;
c. Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;
d. Biochemistry Laboratory, Chemistry Department, Faculty of Science, Assiut University, Assiut 71516, Egypt;
e. Shanghai Turtle Technology Co., Shanghai 201900, China

Funds:

This work was partially supported by grants from National Key R&D Program of China (2019YFA0110802 and 2019YFA0802800), the National Natural Science Foundation of China (32025023, 31971366), and grants from the Shanghai Municipal Commission for Science and Technology (21CJ1402200, 20140900200), the Innovation Program of Shanghai Municipal Education Commission (2019-01-07-00-05-E00054).

Received Date: 2022-04-08
Accepted Date: 2022-06-01
Rev Recd Date: 2022-05-29
Publish Date: 2022-06-09

Abstract

Abstract

CRISPR/Cas9-mediated site-specific insertion of exogenous genes holds potential for clinical applications. However, it is still infeasible because homologous recombination (HR) is inefficient, especially for non-dividing cells. To overcome the challenge, we report that a homology-independent targeted integration (HITI) strategy is used for permanent integration of high-specificity-activity Factor IX variant (F9 Padua, R338L) at the albumin (Alb) locus in a novel hemophilia B (HB) rat model. The knock-in efficiency reaches 3.66%, as determined by droplet digital PCR (ddPCR). The clotting time is reduced to a normal level four weeks after treatment, and the circulating factor IX (FIX) level is gradually increased up to 52% of the normal level over nine months even after partial hepatectomy, demonstrating the amelioration of hemophilia. Through primer-extension-mediated sequencing (PEM-seq), no significant off-target effect is detected. This study not only provides a novel model for HB but also identifies a promising therapeutic approach for rare inherited diseases.
- Hemophilia B,
- Alb,
- FIX,
- CRISPR/Cas9-mediated HITI,
- Gene therapy

FullText(HTML)

References(61)

References

Anguela, X. M., Sharma, R., Doyon, Y., Miller, J. C., Li, H., Haurigot, V., Rohde, M. E., Wong, S. Y., Davidson, R. J., Zhou, S., et al., 2013. Robust ZFN-mediated genome editing in adult hemophilic mice. Blood 122, 3283-3287

Barzel, A., Paulk, N. K., Shi, Y., Huang, Y., Chu, K., Zhang, F., Valdmanis, P. N., Spector, L. P., Porteus, M. H., Gaensler, K. M., et al., 2015. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature 517, 360-364

Chen, H., Shi, M., Gilam, A., Zheng, Q., Zhang, Y., Afrikanova, I., Li, J., Gluzman, Z., Jiang, R., Kong, L. J., et al., 2019. Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII. Scientific reports 9, 16838

Chen, J., An, B., Yu, B., Peng, X., Yuan, H., Yang, Q., Chen, X., Yu, T., Wang, L., Zhang, X., et al., 2021. CRISPR/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs. Haematologica 106, 829-837

Conant, D., Hsiau, T., Rossi, N., Oki, J., Maures, T., Waite, K., Yang, J., Joshi, S., Kelso, R., Holden, K., et al., 2022. Inference of CRISPR Edits from Sanger Trace Data. CRISPR J. 5, 123–130

Conway, A., Mendel, M., Kim, K., McGovern, K., Boyko, A., Zhang, L., Miller, J. C., DeKelver, R. C., Paschon, D. E., Mui, B. L., et al., 2019. Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets. Mol. Ther. 27, 866-877

Cunningham, S. C., Spinoulas, A., Carpenter, K. H., Wilcken, B., Kuchel, P. W., Alexander, I. E., 2009. AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf^ash mice. Mol Ther 17, 1340-1346

Davidoff, A. M., Nathwani, A. C., 2016. Genetic Targeting of the Albumin Locus to Treat Hemophilia. N. Engl. J. Med. 374, 1288-1290

De Caneva, A., Porro, F., Bortolussi, G., Sola, R., Lisjak, M., Barzel, A., Giacca, M., Kay, M. A., Vlahovicek, K., Zentilin, L., et al., 2019. Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases. JCI Insight 5

Doman, J. L., Raguram, A., Newby, G. A., Liu, D. R., 2020. Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors. Nat. Biotechnol. 38, 620-628

Friedman, S. L., 2008. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiological reviews 88, 125-172

Gaj, T., Epstein, B. E., Schaffer, D. V., 2016. Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications. Mol. Ther. 24, 458-464

George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al., 2017. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N. Engl. J. Med. 377, 2215-2227

Gobert, G., Cotillard, A., Fourmestraux, C., Pruvost, L., Miguet, J., Boyer, M., 2018. Droplet digital PCR improves absolute quantification of viable lactic acid bacteria in faecal samples. J. Microbiol. Methods 148, 64-73

Guan, Y., Ma, Y., Li, Q., Sun, Z., Ma, L., Wu, L., Wang, L., Zeng, L., Shao, Y., Chen, Y., et al., 2016. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. EMBO Mol. Med. 8, 477-488

High, K. A., Roncarolo, M. G., 2019. Gene Therapy. N. Engl. J. Med. 381, 455-464

Kung, S. J. B., 1998. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood 91, 784

Laoharawee, K., DeKelver, R. C., Podetz-Pedersen, K. M., Rohde, M., Sproul, S., Nguyen, H. O., Nguyen, T., St Martin, S. J., Ou, L., Tom, S., et al., 2018. Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing. Mol. Ther. 26, 1127-1136

Li, G., Li, X., Zhuang, S., Wang, L., Zhu, Y., Chen, Y., Sun, W., Wu, Z., Zhou, Z., Chen, J., et al., 2022. Gene editing and its applications in biomedicine. Science China. Life sciences 65, 660-700

Li, H., Haurigot, V., Doyon, Y., Li, T., Wong, S. Y., Bhagwat, A. S., Malani, N., Anguela, X. M., Sharma, R., Ivanciu, L., et al., 2011. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475, 217-221

Mao, Z., Bozzella, M., Seluanov, A., Gorbunova, V., 2008. DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell cycle 7, 2902-2906

Maresca, M., Lin, V. G., Guo, N., Yang, Y., 2013. Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining. Genome Res 23, 539-546

Mashimo, T., Takizawa, A., Kobayashi, J., Kunihiro, Y., Yoshimi, K., Ishida, S., Tanabe, K., Yanagi, A., Tachibana, A., Hirose, J., et al., 2012. Generation and characterization of severe combined immunodeficiency rats. Cell Rep. 2, 685-694

Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al., 2017. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N. Engl. J. Med. 377, 1713-1722

Miller, D. G., Petek, L. M., Russell, D. W., 2004. Adeno-associated virus vectors integrate at chromosome breakage sites. Nat. Genet. 36, 767-773

Mitchell, C., Willenbring, H., 2008. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat. Protoc. 3, 1167-1170

Nakade, S., Tsubota, T., Sakane, Y., Kume, S., Sakamoto, N., Obara, M., Daimon, T., Sezutsu, H., Yamamoto, T., Sakuma, T., et al., 2014. Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9. Nat. Commun. 5, 5560

Nathwani, A. C., Tuddenham, E. G., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al., 2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365

Network, C. G. A. R., 2017. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 169, 1327-1341.e1323

Nielsen, L. N., Wiinberg, B., Hager, M., Holmberg, H. L., Hansen, J. J., Roepstorff, K., Tranholm, M., 2014. A novel F8 ^-/- rat as a translational model of human hemophilia A. Journal of thrombosis and haemostasis : JTH 12, 1274-1282

Ohmori, T., Nagao, Y., Mizukami, H., Sakata, A., Muramatsu, S. I., Ozawa, K., Tominaga, S. I., Hanazono, Y., Nishimura, S., Nureki, O., et al., 2017. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. Scientific reports 7, 4159

Ou, L., Przybilla, M. J., Ahlat, O., Kim, S., Overn, P., Jarnes, J., O'Sullivan, M. G., Whitley, C. B., 2020. A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I. Mol. Ther. 28, 1442-1454

Park, C. Y., Kim, D. H., Son, J. S., Sung, J. J., Lee, J., Bae, S., Kim, J. H., Kim, D. W., Kim, J. S., 2015. Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient-Derived iPSCs Using CRISPR-Cas9. Cell stem cell 17, 213-220

Pavani, G., Amendola, M., 2020. Targeted Gene Delivery: Where to Land. Front Genome Ed 2, 609650

Perrin, G. Q., Herzog, R. W., Markusic, D. M., 2019. Update on clinical gene therapy for hemophilia. Blood 133, 407-414

Porro, F., Bortolussi, G., Barzel, A., De Caneva, A., Iaconcig, A., Vodret, S., Zentilin, L., Kay, M. A., Muro, A. F., 2017. Promoterless gene targeting without nucleases rescues lethality of a Crigler-Najjar syndrome mouse model. EMBO Mol. Med 9, 1346-1355

Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al., 2017. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. N. Engl. J. Med. 377, 2519-2530

Rodgers, K., McVey, M., 2016. Error-Prone Repair of DNA Double-Strand Breaks. Journal of cellular physiology 231, 15-24

Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z. F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al., 2017. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390, 849-860

Sabatino, D. E., Nichols, T. C., Merricks, E., Bellinger, D. A., Herzog, R. W., Monahan, P. E., 2012. Animal models of hemophilia. Prog. Mol. Biol. Transl. Sci. 105, 151-209

Schulze, K., Imbeaud, S., Letouze, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al., 2015. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet 47, 505-511

Shao, Y., Guan, Y., Wang, L., Qiu, Z., Liu, M., Chen, Y., Wu, L., Li, Y., Ma, X., Liu, M., et al., 2014. CRISPR/Cas-mediated genome editing in the rat via direct injection of one-cell embryos. Nat. Protoc. 9, 2493-2512

Sharma, R., Anguela, X. M., Doyon, Y., Wechsler, T., DeKelver, R. C., Sproul, S., Paschon, D. E., Miller, J. C., Davidson, R. J., Shivak, D., et al., 2015. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood 126, 1777-1784

Sorensen, K. R., Roepstorff, K., Wiinberg, B., Hansen, A. K., Tranholm, M., Nielsen, L. N., Kjelgaard-Hansen, M., 2016. The F8(-/-) rat as a model of hemophilic arthropathy. Journal of thrombosis and haemostasis : JTH 14, 1216-1225

Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al., 2016. In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature 540, 144-149

Suzuki, K., Yamamoto, M., Hernandez-Benitez, R., Li, Z., Wei, C., Soligalla, R. D., Aizawa, E., Hatanaka, F., Kurita, M., Reddy, P., et al., 2019. Precise in vivo genome editing via single homology arm donor mediated intron-targeting gene integration for genetic disease correction. Cell Res. 29, 804-819

Wang, D., Tai, P. W. L., Gao, G., 2019a. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358-378

Wang, L., Wang, H., Bell, P., McMenamin, D., Wilson, J. M., 2012. Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector. Hum. Gene ther. 23, 533-539

Wang, L., Yang, Y., Breton, C., Bell, P., Li, M., Zhang, J., Che, Y., Saveliev, A., He, Z., White, J., et al., 2020a. A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency. Sci. Adv. 6, eaax5701

Wang, L., Yang, Y., Breton, C. A., White, J., Zhang, J., Che, Y., Saveliev, A., McMenamin, D., He, Z., Latshaw, C., et al., 2019b. CRISPR/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice. Blood 133, 2745-2752

Wang, Q., Zhong, X., Li, Q., Su, J., Liu, Y., Mo, L., Deng, H., Yang, Y., 2020b. CRISPR-Cas9-Mediated In Vivo Gene Integration at the Albumin Locus Recovers Hemostasis in Neonatal and Adult Hemophilia B Mice. Mol. Ther. Methods Clin. Dev. 18, 520-531

Yang, L., Wang, L., Huo, Y., Chen, X., Yin, S., Hu, Y., Zhang, X., Zheng, R., Geng, H., Han, H., et al., 2020. Amelioration of an Inherited Metabolic Liver Disease through Creation of a De Novo Start Codon by Cytidine Base Editing. Mol. Ther. 28, 1673-1683

Yang, Y., Wang, L., Bell, P., McMenamin, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., et al., 2016. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol. 34, 334-338

Yao, X., Wang, X., Hu, X., Liu, Z., Liu, J., Zhou, H., Shen, X., Wei, Y., Huang, Z., Ying, W., et al., 2017. Homology-mediated end joining-based targeted integration using CRISPR/Cas9. Cell Res. 27, 801-814

Yin, J., Liu, M., Liu, Y., Wu, J., Gan, T., Zhang, W., Li, Y., Zhou, Y., Hu, J., 2019. Optimizing genome editing strategy by primer-extension-mediated sequencing. Cell Discov. 5, 18

Yin, S., Ma, L., Shao, T., Zhang, M., Guan, Y., Wang, L., Hu, Y., Chen, X., Han, H., Shen, N., et al., 2022. Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor. Sci. China. Life sci. 65, 718-730

Zhang, J. P., Cheng, X. X., Zhao, M., Li, G. H., Xu, J., Zhang, F., Yin, M. D., Meng, F. Y., Dai, X. Y., Fu, Y. W., et al., 2019. Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse. Genome Biol. 20, 276

Zhang, X., Wang, L., Liu, M., Li, D., 2017. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy. Sci. China. Life sci. 60, 468-475

Zhao, H., Li, Y., He, L., Pu, W., Yu, W., Li, Y., Wu, Y. T., Xu, C., Wei, Y., Ding, Q., et al., 2020. In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia. Circulation 141, 67-79

Zheng, R., Fang, X., Chen, X., Huang, Y., Xu, G., He, L., Li, Y., Niu, X., Yang, L., Wang, L., et al., 2020. Knockdown of lactate dehydrogenase by adeno-associated virus-delivered CRISPR/Cas9 system alleviates primary hyperoxaluria type 1. Clin. Transl Med. 10, e261

Zheng, S., Geghman, K., Shenoy, S., Li, C., 2012. Retake the center stage--new development of rat genetics. J. Genet. Genomics 39, 261-268

Relative Articles

Supplements(0)

Cited By

Proportional views